Article PDF
Avoid common mistakes on your manuscript.
References
Brien, G.L., Valerio, D.G., and Armstrong, S.A. (2016). Exploiting the epigenome to control cancer-promoting gene-expression programs. Cancer Cell 29, 464–476.
Falkenberg, K.J., and Johnstone, R.W. (2014). Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13, 673–691.
Garraway, L.A., and Lander, E.S. (2013). Lessons from the cancer genome. Cell 153, 17–37.
Jenuwein, T., and Allis, C.D. (2001). Translating the histone code. Science 293, 1074–1080.
Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R., and Pazdur, R. (2007). FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12, 1247–1252.
Mazur, P.K., Herner, A., Mello, S.S., Wirth, M., Hausmann, S., Sánchez-Rivera, F.J., Lofgren, S.M., Kuschma, T., Hahn, S.A., Vangala, D., Trajkovic-Arsic, M., Gupta, A., Heid, I., Noë l, P.B., Braren, R., Erkan, M., Kleeff, J., Sipos, B., Sayles, L.C., Heikenwalder, M., Heßmann, E., Ellenrieder, V., Esposito, I., Jacks, T., Bradner, J.E., Khatri, P., Sweet-Cordero, E.A., Attardi, L.D., Schmid, R.M., Schneider, G., Sage, J., and Siveke, J.T. (2015). Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med 21, 1163–1171.
Mercurio, C., Minucci, S., and Pelicci, P.G. (2010). Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 62, 18–34.
Min, H.Y., Lee, S.C., Woo, J.K., Jung, H.J., Park, K.H., Jeong, H.M., Hyun, S.Y., Cho, J., Lee, W., Park, J.E., Kwon, S.J., Lee, H.J., Ni, X., Shin, Y.K., Johnson, F.M., Duvic, M., and Lee, H.Y. (2016). Essential role of DNA methyltransferase 1-mediated transcription of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors. Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-0534.
Nightingale, K.P., O’Neill, L.P., and Turner, B.M. (2006). Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genets Dev 16, 125–136.
Pei, Y., Liu, K.W., Wang, J., Garancher, A., Tao, R., Esparza, L.A., Maier, D.L., Udaka, Y.T., Murad, N., Morrissy, S., Seker-Cin, H., Brabetz, S., Qi, L., Kogiso, M., Schubert, S., Olson, J.M., Cho, Y.J., Li, X.N., Crawford, J.R., Levy, M.L., Kool, M., Pfister, S.M., Taylor, M.D., and Wechsler-Reya, R.J. (2016). HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma. Cancer Cell 29, 311–323.
Slingerland, M., Guchelaar, H.J., and Gelderblom, H. (2014). Histone deacetylase inhibitors. Anti-Cancer Drugs 25, 140–149.
Thiagalingam, S., Cheng, K.H., Lee, H.J., Mineva, N., Thiagalingam, A., and Ponte, J.F. (2003). Histone deacetylases: unique players in shaping the epigenetic histone code. Ann New York Acad Sci 983, 84–100.
Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., and Kinzler, K.W. (2013). Cancer genome landscapes. Science 339, 1546–1558.
Zeng, H., Qu, J., Jin, N., Xu, J., Lin, C., Chen, Y., Yang, X., He, X., Tang, S., Lan, X., Yang, X., Chen, Z., Huang, M., Ding, J., and Geng, M. (2016). Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer. Cancer Cell 30, 459–473.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Huang, M., Geng, M. Exploiting histone deacetylases for cancer therapy: from hematological malignancies to solid tumors. Sci. China Life Sci. 60, 94–97 (2017). https://doi.org/10.1007/s11427-016-0300-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-016-0300-y